# Pancreatic Cancer Pancreatic cancer is one of the most difficult treatment settings in oncology, which makes any human curcumin data here especially notable. ### Overview Pancreatic cancer — most commonly pancreatic ductal adenocarcinoma (PDAC) — carries one of the poorest prognoses of any cancer type. Five-year survival remains below 12% overall, and for patients with advanced or metastatic disease, treatment options are limited and outcomes remain deeply difficult. It is precisely because of this that any compound showing a human-level clinical signal in pancreatic cancer deserves close attention. Curcumin has been tested in patients with advanced pancreatic cancer — including those who had already failed gemcitabine-based chemotherapy — and has generated meaningful safety and early efficacy data across multiple trials. Its biological profile in PDAC is exceptionally relevant: it targets the NF-κB and STAT3 pathways that drive pancreatic tumour survival, interferes with the dense fibrous stroma that physically protects tumours from treatment, suppresses cancer stem cells responsible for gemcitabine resistance, and has shown radiosensitising effects in laboratory models. This is not a treatment — but it is a compound with a genuinely compelling scientific rationale in one of oncology's hardest settings. *** ### Why Pancreatic Cancer Is Biologically Suited to Curcumin PDAC has several features that make it particularly resistant to standard treatment and that curcumin's mechanisms directly address: * NF-κB is constitutively activated in the vast majority of pancreatic tumours — meaning it is permanently switched on, driving inflammation, resistance to apoptosis, and evasion of chemotherapy. Curcumin is a well-characterised NF-κB inhibitor. * STAT3 signalling — activated downstream of IL-6 — promotes tumour cell proliferation and survival in PDAC. Curcumin reduces IL-6 expression and phosphorylated STAT3 levels in pancreatic cancer cells, reducing both proliferative and anti-apoptotic capacity. * The desmoplastic stroma — a dense wall of fibrous tissue generated by pancreatic stellate cells (PSCs) — makes up more than 80% of pancreatic tumour mass in many patients. It physically limits drug penetration, creates a hypoxic environment that drives invasion, and suppresses immune activity. Curcumin has shown direct activity against PSCs, reducing this stromal barrier. * COX-2/PGE2 signalling amplifies the inflammatory tumour microenvironment in PDAC. Curcumin interferes with this pathway at multiple levels. * Gemcitabine resistance — the central treatment challenge in PDAC — is partly driven by cancer stem cell subpopulations and epigenetic regulators. Curcumin has shown the ability to reverse this resistance through mechanisms that go deeper than most compounds. *** ### Gemcitabine Resistance: A Detailed Look Gemcitabine is the backbone of pancreatic cancer chemotherapy, yet resistance — both acquired and inherent — is a defining problem in PDAC. This has made curcumin's demonstrated ability to resensitise gemcitabine-resistant cells one of the most important findings in this research area. A 2017 study using gemcitabine-resistant PDAC cell lines found that curcumin restored sensitivity to gemcitabine by targeting the PRC2-PVT1-c-Myc epigenetic axis. In plain terms: gemcitabine-resistant pancreatic cancer cells upregulate an epigenetic regulator called EZH2 (part of the PRC2 complex) and a long non-coding RNA called PVT1, which together maintain cancer stem cell identity and chemoresistance. Curcumin specifically downregulated EZH2 and PVT1, dismantling this resistance mechanism. In a mouse xenograft model using gemcitabine-resistant tumours, gemcitabine alone had almost no effect on tumour growth — but daily curcumin treatment significantly suppressed tumour growth, and the combination of both further enhanced tumour control. The same study showed that curcumin suppressed cancer stem cell-enriched spheroid formation in gemcitabine-resistant cells — a critical finding, since these spheroids represent the self-renewing subpopulation most responsible for relapse and treatment failure. An earlier foundational study demonstrated that restoring gemcitabine sensitivity in pancreatic cancer cells was achievable through curcumin-mediated downregulation of NF-κB and the cancer stem cell markers CXCR4 and CD44. This study showed that resistant cells treated with curcumin had their stem-like properties reduced alongside their resistance profile — a two-for-one effect that is difficult to achieve with conventional agents. A 2020 study confirmed synergistic anti-cancer effects when curcumin was combined with either gemcitabine or docetaxel in pancreatic cancer cell lines, and identified the mechanism as cooperative inhibition of cell survival and proliferation pathways beyond what either compound achieved alone. *** ### The Desmoplastic Stroma: Curcumin's Structural Target The desmoplastic stroma of PDAC is one of the most significant barriers to effective treatment in any modality. Pancreatic stellate cells (PSCs) are the primary architects of this stroma: when activated, they lay down dense collagen networks around tumours that block drug delivery, generate hypoxia, and create a growth-permissive niche for cancer cells. Laboratory studies have shown that curcumin inhibits PSC proliferation and survival in a dose-dependent manner. Under hypoxic conditions — which are routinely present in PDAC tumours — curcumin has been shown to suppress tumour-stromal crosstalk via the IL-6/ERK/NF-κB axis, reducing pancreatic cancer cell invasion and EMT (the process by which cancer cells become more motile and metastatic). Specifically, curcumin counteracted PSC-conditioned media-driven increases in phosphorylated ERK and phosphorylated NF-κB, and reduced the expression of the invasion markers vimentin, MMP-9, and N-cadherin. This is significant because it means curcumin may not just be targeting the cancer cells themselves — it may be softening the structural fortress that makes PDAC so impenetrable to treatment. *** ### Radiosensitisation Radiation is increasingly used in locally advanced pancreatic cancer, either as stereotactic body radiotherapy (SBRT) or as part of combined chemoradiation. Pancreatic tumours are characterised by radioresistance, partly due to their hypoxic, stromal-dense environment. A 2020 laboratory study found that curcumin significantly enhanced radiation-induced apoptosis in both Panc-1 and MiaPaCa-2 pancreatic cancer cell lines. In the more radioresistant Panc-1 cell line, curcumin produced significant radiosensitisation, as evidenced by increased DNA double-strand breaks (γH2AX phosphorylation), greater G2/M cell-cycle arrest, and higher overall cell death compared with radiation alone. The authors specifically noted that patients with more radioresistant pancreatic tumours could potentially benefit from curcumin as a concurrent phytotherapeutic during radiotherapy. *** ### Human Clinical Trial Data ### Phase II Monotherapy Trial — Dhillon et al. The most cited clinical study of curcumin in pancreatic cancer enrolled 21 patients with advanced disease and tested oral curcumin at 8 g/day as monotherapy. Despite the notoriously poor response rates in this setting, two patients showed clinically relevant biological activity: one patient achieved a brief but documented partial response (73% tumour reduction, though this was not sustained), and a second patient demonstrated prolonged stable disease with a 26% reduction in tumour marker CA19-9. NF-κB activity was measurably downregulated in peripheral blood mononuclear cells in the majority of patients assessed, providing direct biological evidence that curcumin was reaching and engaging its target at the molecular level. The treatment was safe throughout, with no dose-limiting toxicity identified — a critical finding given the typically compromised health status of patients in this setting. ### Phase I/II Combination Trial — Kanai et al. (Japan) A Japanese Phase I/II trial tested curcumin in combination with gemcitabine-based chemotherapy specifically in patients who had already become resistant to gemcitabine — one of the hardest patient populations to treat in all of oncology. Patients received curcumin at doses up to 8 g/day alongside their chemotherapy. Median survival time was 5.4 months and the 1-year survival rate was 19% in this heavily pre-treated group — results the authors described as promising in the context of gemcitabine-resistant disease, where prognosis is particularly poor. Importantly, no cumulative toxicity was observed, and four patients were able to maintain curcumin intake for over six months. ### Pilot Combination Trial — Epelbaum et al. (Israel) A pilot trial in 17 chemotherapy-naive patients with advanced pancreatic cancer combined standard-dose gemcitabine with 8 g/day oral curcumin. Curcumin demonstrated antiproliferative activity and potentiated the anti-tumour effect of gemcitabine. Dose reduction to 4 g/day was required in two patients due to gastrointestinal discomfort, suggesting that 8 g/day may be at the upper tolerable limit when combined with gemcitabine — an important dosing signal for future trial design. *** ### Inflammatory Pathway Analysis: 2025 Update A 2025 mechanistic review using transcriptome sequencing of curcumin-treated pancreatic cancer cells confirmed significant inhibition of 12 key inflammatory mRNA targets: CASP1, CCL2, CSF2, HMGB1, IL-1A, IL-1B, IL-1RN, IL-6, NLRP3, S100A9, TLR3, and TLR4. Single-cell analysis confirmed that curcumin's inflammatory modulation concentrated in the monocyte/macrophage population within the tumour microenvironment — the cell types most responsible for creating the immunosuppressive environment that shields PDAC from immune attack. This level of mechanistic detail — mapped to specific immune cell populations — represents a meaningful advance in understanding how curcumin may be contributing to anti-tumour effects in this setting. *** ### Practical Interpretation for Patients Pancreatic cancer is one of the settings where curcumin's multi-target profile becomes most compelling. The reasons are structural: * It targets NF-κB and STAT3 — the core survival drivers in PDAC * It directly addresses gemcitabine resistance via epigenetic and cancer stem cell mechanisms * It interferes with the desmoplastic stroma that physically protects pancreatic tumours from treatment * It has shown radiosensitising effects in radioresistant cell lines * It has been tested in human patients — including in gemcitabine-resistant disease — and found to be safe and reasonably well tolerated * Biological activity at the molecular level (NF-κB downregulation in patient blood cells) has been confirmed in a clinical setting The evidence does not establish curcumin as a stand-alone treatment for pancreatic cancer. What it does establish is a biologically coherent rationale for its investigation as an adjunct, supported by safety data from small but genuine human trials. For patients and families navigating pancreatic cancer, this is meaningful context — and reason to discuss it with the treating team. Bioavailability remains a significant limiting factor in translating these findings. Liposomal or piperine-combined curcumin preparations are the formulations most likely to achieve tissue-level concentrations relevant to the laboratory findings described here. *** ### References for Curcumin in Pancreatic Cancer **MCS Formulas Curcumin C3 Pro Liposomal:**\ *If using MCS Formulas, the discount code **`abbey5`** gives 5% off and supports patients' worldwide access to more free Healing Cancer Study Support resources.* Phase II trial of curcumin in patients with advanced pancreatic cancer — Dhillon et al.\ Curcumin and gemcitabine in patients with advanced pancreatic cancer — Epelbaum et al., pilot clinical trial\ Therapeutic applications of curcumin for patients with pancreatic cancer — Kanai et al., Phase I/II review including gemcitabine-resistant population\ Curcumin sensitizes pancreatic cancer cells to gemcitabine by inhibiting the PRC2-PVT1-c-Myc axis — Yoshida et al.\ Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of cancer stem cell markers — Ali et al.\ Curcumin enhances anti-cancer efficacy of gemcitabine or docetaxel in pancreatic cancer — synergistic combination study\ Curcumin inhibits pancreatic cancer cell invasion and EMT by interfering with tumour-stromal crosstalk via the IL-6/ERK/NF-κB axis\ Antiproliferative effects of curcumin analog L49H37 on pancreatic stellate cells — targeting the desmoplastic stroma\ Modification of radiosensitivity by curcumin in human pancreatic cancer cell lines Panc-1 and MiaPaCa-2\ Mechanistic insights into curcumin's anti-inflammatory effects in pancreatic cancer — transcriptome analysis 2025\ Sensitising PDAC to gemcitabine by suppressing NF-κB — curcumin mechanisms review 2026\ Phase II trial of curcumin in patients with advanced pancreatic cancer\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/curcumin-evidence-by-cancer-type/pancreatic-cancer.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.